Torsdag 18 December | 14:06:32 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-11-05 09:00 Kvartalsrapport 2026-Q3
2026-08-20 09:00 Kvartalsrapport 2026-Q2
2026-05-21 N/A Årsstämma
2026-05-07 09:00 Kvartalsrapport 2026-Q1
2026-03-31 08:00 Bokslutskommuniké 2025
2025-12-17 - Extra Bolagsstämma 2026
2025-11-25 - Split SUBGEN 1000:1
2025-11-05 - Extra Bolagsstämma 2025
2025-08-29 - Kvartalsrapport 2025-Q2
2025-07-01 - X-dag ordinarie utdelning SUBGEN 0.00 SEK
2025-06-30 - Årsstämma
2025-03-05 - Bokslutskommuniké 2024
2024-11-15 - Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-07-01 - X-dag ordinarie utdelning SUBGEN 0.00 SEK
2024-06-28 - Årsstämma
2024-04-26 - Extra Bolagsstämma 2024
2024-03-29 - Bokslutskommuniké 2023
2023-11-24 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-06-22 - Årsstämma
2023-06-01 - Kvartalsrapport 2023-Q1
2023-05-16 - X-dag ordinarie utdelning SUBGEN 0.00 SEK
2023-03-31 - Bokslutskommuniké 2022
2023-01-20 - Extra Bolagsstämma 2022
2022-11-23 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-06-21 - X-dag ordinarie utdelning SUBGEN 0.00 SEK
2022-06-20 - Årsstämma
2022-05-25 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-11-23 - Kvartalsrapport 2021-Q3
2021-08-24 - Kvartalsrapport 2021-Q2
2021-06-29 - X-dag ordinarie utdelning SUBGEN 0.00 SEK
2021-06-28 - Årsstämma
2021-05-25 - Kvartalsrapport 2021-Q1
2021-03-09 - Extra Bolagsstämma 2021
2021-02-26 - Bokslutskommuniké 2020
2020-11-27 - Kvartalsrapport 2020-Q3
2020-08-27 - Kvartalsrapport 2020-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Subgen AI utvecklar både infrastruktur och proprietär agentcentrerad AI-as-a-Service-programvara, med varumärket Serenity Star. Bolagets lösningar är utformade för att skala upp och accelerera implementeringen av AI i organisationer. Subgen AI levererar tjänster till kunder inom sektorer som hälso- och sjukvård, energi, juridik och personal. Subgen AI är verksamt i Europa, Latinamerika och USA.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2024-07-08 09:59:00

Lund 8 July 2024 — AegirBio AB, a forefront leader in saliva-based diagnostics solutions, announces today that Melissa Grant, BSc, MSc, PhD, Associate Professor at the University of Birmingham’s School of Dentistry, has joined the company’s Scientific Advisory Board. Professor Grant brings a wealth of expertise in the biochemistry of saliva and its applications in disease detection.

"We are thrilled to welcome Melissa Grant to our Scientific Advisory Board," said Marco Witteveen, CEO. "Her extensive research in biochemistry and her innovative approach to disease detection will be invaluable as we continue to advance our scientific initiatives."

Melissa Grant is co-lead of the Periodontal Research Group at the University of Birmingham and has published over 70 peer-reviewed scientific papers, reviews, and book chapters. Her research focuses on the use of proteomics for discovering novel biomarkers and understanding the mechanisms of inflammatory diseases, including those affecting the heart, oral cavity, and kidneys in humans and animals.

In addition to her research achievements, Professor Grant serves as the Postgraduate Research Lead, Equality, Diversity, and Inclusion Lead, and Curator of the Open Wide exhibition space at the School of Dentistry. She is also a dedicated Public Engagement Ambassador, furthering the reach and impact of her work within the community.